Compare ADMA Biologics Inc (ADMA) vs Gitlab Inc (GTLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Gitlab Inc — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Gitlab Inc trades at $31.87 (market cap $5.50B). The key difference: Gitlab Inc is far larger — about 2.6× ADMA Biologics Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | GTLB | |
|---|---|---|
Market Cap | $2.13B | $5.50B |
Sector | Health | Technology |
52-Week High | $20.38 | $51.04 |
52-Week Low | $7.60 | $19.42 |
Enterprise Value | $2.20B | $4.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
GitLab (GTLB) trades at $32.59, up 1.62% today, with a bullish technical signal and recent earnings beats. The stock shows strong revenue growth, reaching $759 million in 2025, but remains unprofitable with a negative net margin. Analyst sentiment is mixed, with a consensus price target of $31.86, while recent news highlights its leadership in DevSecOps and AI-driven software development.
Outlook: GitLab's growth trajectory and strategic position in AI and DevSecOps present upside potential, but profitability concerns and high valuation ratios pose risks. Investors should weigh strong revenue expansion against ongoing losses and competitive pressures in the technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
